Kintegral Advisory LLC Has $3.80 Million Stock Position in Boston Scientific Corporation (NYSE:BSX)

Kintegral Advisory LLC cut its holdings in shares of Boston Scientific Corporation (NYSE:BSX - Free Report) by 32.9% in the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 37,622 shares of the medical equipment provider's stock after selling 18,451 shares during the period. Kintegral Advisory LLC's holdings in Boston Scientific were worth $3,795,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also modified their holdings of the company. Catalyst Capital Advisors LLC increased its stake in Boston Scientific by 45.2% during the first quarter. Catalyst Capital Advisors LLC now owns 1,580 shares of the medical equipment provider's stock valued at $159,000 after purchasing an additional 492 shares during the last quarter. SMART Wealth LLC lifted its holdings in Boston Scientific by 6.1% in the first quarter. SMART Wealth LLC now owns 6,114 shares of the medical equipment provider's stock worth $617,000 after acquiring an additional 352 shares during the last quarter. Harel Insurance Investments & Financial Services Ltd. acquired a new position in Boston Scientific in the first quarter valued at approximately $439,000. IFM Investors Pty Ltd raised its position in shares of Boston Scientific by 8.7% during the 1st quarter. IFM Investors Pty Ltd now owns 309,327 shares of the medical equipment provider's stock worth $31,205,000 after purchasing an additional 24,762 shares during the period. Finally, OneDigital Investment Advisors LLC lifted its holdings in shares of Boston Scientific by 14.5% in the 1st quarter. OneDigital Investment Advisors LLC now owns 10,843 shares of the medical equipment provider's stock worth $1,094,000 after purchasing an additional 1,371 shares during the last quarter. 89.07% of the stock is owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In other Boston Scientific news, EVP Arthur C. Butcher sold 17,314 shares of the business's stock in a transaction on Thursday, May 1st. The shares were sold at an average price of $102.06, for a total value of $1,767,066.84. Following the sale, the executive vice president owned 22,235 shares of the company's stock, valued at $2,269,304.10. The trade was a 43.78% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, EVP Joseph Michael Fitzgerald sold 56,372 shares of the firm's stock in a transaction dated Wednesday, June 4th. The stock was sold at an average price of $102.88, for a total transaction of $5,799,551.36. Following the transaction, the executive vice president directly owned 178,342 shares of the company's stock, valued at $18,347,824.96. The trade was a 24.02% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 461,970 shares of company stock valued at $47,755,193 in the last ninety days. 0.50% of the stock is currently owned by insiders.

Boston Scientific Stock Performance

Boston Scientific stock traded up $0.67 during mid-day trading on Friday, reaching $104.30. The company had a trading volume of 2,931,148 shares, compared to its average volume of 6,658,145. The company has a 50 day moving average of $103.42 and a 200-day moving average of $100.05. Boston Scientific Corporation has a 52 week low of $71.88 and a 52 week high of $107.53. The company has a quick ratio of 0.88, a current ratio of 1.45 and a debt-to-equity ratio of 0.47. The firm has a market cap of $154.30 billion, a price-to-earnings ratio of 76.13, a PEG ratio of 2.71 and a beta of 0.68.

Boston Scientific (NYSE:BSX - Get Free Report) last released its earnings results on Wednesday, April 23rd. The medical equipment provider reported $0.75 earnings per share for the quarter, topping analysts' consensus estimates of $0.67 by $0.08. The business had revenue of $4.66 billion for the quarter, compared to the consensus estimate of $4.57 billion. Boston Scientific had a return on equity of 18.67% and a net margin of 11.58%. The firm's revenue for the quarter was up 20.9% compared to the same quarter last year. During the same period last year, the business earned $0.56 earnings per share. On average, sell-side analysts expect that Boston Scientific Corporation will post 2.85 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of analysts recently weighed in on the stock. Wall Street Zen raised shares of Boston Scientific from a "hold" rating to a "buy" rating in a report on Tuesday, April 29th. Citigroup reaffirmed a "buy" rating and issued a $125.00 price objective (up previously from $119.00) on shares of Boston Scientific in a report on Thursday, May 22nd. Truist Financial raised their target price on shares of Boston Scientific from $113.00 to $117.00 and gave the company a "buy" rating in a research note on Thursday, April 24th. Barclays upped their price target on shares of Boston Scientific from $118.00 to $125.00 and gave the stock an "overweight" rating in a research note on Friday, April 25th. Finally, Leerink Partners began coverage on shares of Boston Scientific in a research note on Monday, June 16th. They set an "outperform" rating and a $118.00 price objective on the stock. Twenty-two investment analysts have rated the stock with a buy rating and three have assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of "Buy" and an average target price of $116.09.

Boston Scientific Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.